From our in-house cohort and online database analysis, we found that the majority of the patients with pancreatic cancer exhibited deficiencies in both ASS1 and OTC enzymes, suggesting that the combination of arginine deprivation and canavanine could be particularly effective in these patients. This evidence concerns the gene ASS1 and familial pancreatic carcinoma.